Tetherex Pharmaceuticals
Company Details
Status: Private
Employees: 11-50
Location:
Oklahoma City, OK
Type:
sample
Technology:
sample
sample
sample
About: Tetherex Pharmaceuticals, a clinical-stage drug development company, was formed in 2014 as a spin-off of Selexys Pharmaceuticals to develop novel first-in-class therapeutics targeting cell adhesion proteins in inflammatory and oncologic diseases. Based on pioneering scientific work on the molecular mechanisms of cell adhesion and inflammation by our founding scientists, Tetherex is advancing new breakthrough therapeutics. Our lead selectin inhibitor clinical program is focused on a functionally blocking anti-PSGL-1 antibody called SelK2 which is currently under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Tetherex has also acquired an exclusive worldwide license from Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform which is currently under investigation as a vaccine for COVID-19. We invite you to explore our website and learn more about our highly experienced management team and our clinical development programs
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Tetherex Pharmaceuticals | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.